Compare FSP & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSP | ATNM |
|---|---|---|
| Founded | 1981 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3M | 37.1M |
| IPO Year | 2001 | 2013 |
| Metric | FSP | ATNM |
|---|---|---|
| Price | $0.37 | $1.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.60 |
| AVG Volume (30 Days) | ★ 783.1K | 110.5K |
| Earning Date | 10-27-2026 | 11-13-2026 |
| Dividend Yield | ★ 5.88% | N/A |
| EPS Growth | ★ 15.69 | 14.17 |
| EPS | N/A | ★ 0.71 |
| Revenue | ★ $107,162,000.00 | $90,000.00 |
| Revenue This Year | $16.75 | $19,344.45 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.54 |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $0.30 | $0.74 |
| 52 Week High | $1.49 | $1.74 |
| Indicator | FSP | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 53.44 | 40.39 |
| Support Level | $0.32 | $0.98 |
| Resistance Level | $0.38 | $1.13 |
| Average True Range (ATR) | 0.02 | 0.06 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 76.74 | 8.70 |
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.